NCT04167917View on ClinicalTrials.gov

NTX-301 in MDS/AML

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

January 6, 2021

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions
Acute Myeloid LeukemiaMyelodysplastic SyndromesChronic Myelomonocytic Leukemia
Interventions
DRUG

NTX-301

oral hypomethylating agent

Trial Locations (2)

35294

University of Alabama at Birmingham, Birmingham

53226

Medical College of Wisconsin, Milwaukee

All Listed Sponsors
lead

University of Alabama at Birmingham

OTHER